The FDA on April 22, 2024, the Food and Drug Administration approved ANKTIVA® with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in Situ (CIS) with or without papillary tumors. ANKTIVA® is a product of Altor BioScience, LLC.
Bottom Ad
Advertisement
Subscribe
